Mangrove Partners’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Mangrove Partners’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-500,000	Closed	-$4.93M	–	630
2022 Q1	$4.93M	Buy	+500,000	New	+$4.92M	0.27%	108
2021 Q4	–	Sell	-300,000	Closed	-$2.92M	–	600
2021 Q3	$2.92M	Hold	300,000	–	–	0.26%	116
2021 Q2	$2.9M	Hold	300,000	–	–	0.3%	93
2021 Q1	$2.92M	Buy	+300,000	New	+$2.91M	0.29%	92

Other funds holding BIOT

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CCP

Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Cohanzick Management Pleasantville, New York $231K AUM 3.17% 1-Year Est. Return

RiverPark Advisors New York $219M AUM 14.91% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Mangrove Partners's BIOT Position: Q2 2022 in Review

Mangrove Partners sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q2 2022, closing a stake of 500,000 shares — an estimated $4.93M sold.

Mangrove Partners first reported a position in BIOT in Q1 2021 and held it in 4 quarters. The position peaked at $4.93M in Q1 2022. 67 funds tracked by Wall St. Rank hold BIOT as of Q2 2022.

Mangrove Partners reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q2 2022 after selling out during the quarter.
Mangrove Partners sold 500,000 Biotech Acquisition Company Class A Ordinary Shares shares in Q2 2022, an estimated $4.93M.
Mangrove Partners first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2021 and held it in 4 quarters.
Mangrove Partners's Biotech Acquisition Company Class A Ordinary Shares position peaked at $4.93M in Q1 2022.
67 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q2 2022.

Based on Mangrove Partners's 13F filing for Q2 2022, filed 15 Aug 2022.